Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19 - Seite 2
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering
targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the
complement cascade, including those within hematology, ophthalmology, and nephrology. For more information, please visit http://apellis.com.
Lesen Sie auch
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, such as the statements regarding the timing of enrollment of clinical trials, as well as any other statements
regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the
company’s clinical trials will be fully enrolled and completed when anticipated; uncertainties regarding the impact of the COVID-19 pandemic on the company’s business and operations, including the
timing and conduct of its ongoing clinical trials; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial or of other trials; whether
results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether the results of the company’s clinical trials will
warrant regulatory submissions and whether APL-9 will receive approval from the FDA or equivalent foreign regulatory agencies for respiratory failure secondary to COVID-19 or any other indication
when expected or at all; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 29, 2020 and the risks described in other filings that Apellis may make with
the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new information, future events or otherwise.